Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress

Gethin R. Ellis; Angus K. Nightingale; Daniel J. Blackman; Richard A. Anderson; Catherine Mumford; Graham Timmins; Derek Lang; Simon K. Jackson; Michael D. Penney; Malcolm J. Lewis; Michael P. Frenneaux; Jayne Morris-Thurgood

doi:10.1016/S1388-9842(02)00002-8

Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress

Gethin R. Ellis, Angus K. Nightingale, Daniel J. Blackman, Richard A. Anderson, Catherine Mumford, Graham Timmins, Derek Lang, Simon K. Jackson, Michael D. Penney, Malcolm J. Lewis, Michael P. Frenneaux, Jayne Morris-Thurgood

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Angiotensin II exerts a number of harmful effects in patients with chronic heart failure (CHF) and, through an increase in oxidative stress, is thought to be critical in the development of endothelial dysfunction. Angiotensin II may be elevated in CHF despite treatment with angiotensin converting enzyme (ACE) inhibitors, producing a rationale for adjunctive angiotensin receptor blockade. We investigated whether the addition of angiotensin antagonism to ACE inhibition would reduce oxidative stress and improve endothelial function and exercise tolerance in patients with chronic heart failure.

Original language	English
Pages (from-to)	193-199
Number of pages	7
Journal	European Journal of Heart Failure
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/S1388-9842(02)00002-8
Publication status	Published - Mar 2002

Keywords

Adult
Aged
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Benzimidazoles
Blood Pressure
Brachial Artery
Chronic Disease
Drug Therapy, Combination
Endothelium, Vascular
Exercise Tolerance
Female
Follow-Up Studies
Heart Failure
Heart Rate
Humans
Lipid Peroxidation
Male
Middle Aged
Natriuretic Peptide, Brain
Oxidative Stress
Stroke Volume
Tetrazoles
Time Factors
Treatment Outcome

Access to Document

10.1016/S1388-9842(02)00002-8

Cite this

Ellis, G. R., Nightingale, A. K., Blackman, D. J., Anderson, R. A., Mumford, C., Timmins, G., Lang, D., Jackson, S. K., Penney, M. D., Lewis, M. J., Frenneaux, M. P., & Morris-Thurgood, J. (2002). Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. European Journal of Heart Failure, 4(2), 193-199. https://doi.org/10.1016/S1388-9842(02)00002-8

Ellis, Gethin R. ; Nightingale, Angus K. ; Blackman, Daniel J. ; Anderson, Richard A. ; Mumford, Catherine ; Timmins, Graham ; Lang, Derek ; Jackson, Simon K. ; Penney, Michael D. ; Lewis, Malcolm J. ; Frenneaux, Michael P. ; Morris-Thurgood, Jayne. / Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. In: European Journal of Heart Failure. 2002 ; Vol. 4, No. 2. pp. 193-199.

@article{8560ba4796a04a8184d48c95d8725c4e,

title = "Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress",

abstract = "Angiotensin II exerts a number of harmful effects in patients with chronic heart failure (CHF) and, through an increase in oxidative stress, is thought to be critical in the development of endothelial dysfunction. Angiotensin II may be elevated in CHF despite treatment with angiotensin converting enzyme (ACE) inhibitors, producing a rationale for adjunctive angiotensin receptor blockade. We investigated whether the addition of angiotensin antagonism to ACE inhibition would reduce oxidative stress and improve endothelial function and exercise tolerance in patients with chronic heart failure.",

keywords = "Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Blood Pressure, Brachial Artery, Chronic Disease, Drug Therapy, Combination, Endothelium, Vascular, Exercise Tolerance, Female, Follow-Up Studies, Heart Failure, Heart Rate, Humans, Lipid Peroxidation, Male, Middle Aged, Natriuretic Peptide, Brain, Oxidative Stress, Stroke Volume, Tetrazoles, Time Factors, Treatment Outcome",

author = "Ellis, {Gethin R.} and Nightingale, {Angus K.} and Blackman, {Daniel J.} and Anderson, {Richard A.} and Catherine Mumford and Graham Timmins and Derek Lang and Jackson, {Simon K.} and Penney, {Michael D.} and Lewis, {Malcolm J.} and Frenneaux, {Michael P.} and Jayne Morris-Thurgood",

year = "2002",

month = mar,

doi = "10.1016/S1388-9842(02)00002-8",

language = "English",

volume = "4",

pages = "193--199",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley",

number = "2",

}

Ellis, GR, Nightingale, AK, Blackman, DJ, Anderson, RA, Mumford, C, Timmins, G, Lang, D, Jackson, SK, Penney, MD, Lewis, MJ, Frenneaux, MP & Morris-Thurgood, J 2002, 'Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress', European Journal of Heart Failure, vol. 4, no. 2, pp. 193-199. https://doi.org/10.1016/S1388-9842(02)00002-8

Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. / Ellis, Gethin R.; Nightingale, Angus K.; Blackman, Daniel J.; Anderson, Richard A.; Mumford, Catherine; Timmins, Graham; Lang, Derek; Jackson, Simon K.; Penney, Michael D.; Lewis, Malcolm J.; Frenneaux, Michael P.; Morris-Thurgood, Jayne.

In: European Journal of Heart Failure, Vol. 4, No. 2, 03.2002, p. 193-199.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress

AU - Ellis, Gethin R.

AU - Nightingale, Angus K.

AU - Blackman, Daniel J.

AU - Anderson, Richard A.

AU - Mumford, Catherine

AU - Timmins, Graham

AU - Lang, Derek

AU - Jackson, Simon K.

AU - Penney, Michael D.

AU - Lewis, Malcolm J.

AU - Frenneaux, Michael P.

AU - Morris-Thurgood, Jayne

PY - 2002/3

Y1 - 2002/3

N2 - Angiotensin II exerts a number of harmful effects in patients with chronic heart failure (CHF) and, through an increase in oxidative stress, is thought to be critical in the development of endothelial dysfunction. Angiotensin II may be elevated in CHF despite treatment with angiotensin converting enzyme (ACE) inhibitors, producing a rationale for adjunctive angiotensin receptor blockade. We investigated whether the addition of angiotensin antagonism to ACE inhibition would reduce oxidative stress and improve endothelial function and exercise tolerance in patients with chronic heart failure.

AB - Angiotensin II exerts a number of harmful effects in patients with chronic heart failure (CHF) and, through an increase in oxidative stress, is thought to be critical in the development of endothelial dysfunction. Angiotensin II may be elevated in CHF despite treatment with angiotensin converting enzyme (ACE) inhibitors, producing a rationale for adjunctive angiotensin receptor blockade. We investigated whether the addition of angiotensin antagonism to ACE inhibition would reduce oxidative stress and improve endothelial function and exercise tolerance in patients with chronic heart failure.

KW - Adult

KW - Aged

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Antihypertensive Agents

KW - Benzimidazoles

KW - Blood Pressure

KW - Brachial Artery

KW - Chronic Disease

KW - Drug Therapy, Combination

KW - Endothelium, Vascular

KW - Exercise Tolerance

KW - Female

KW - Follow-Up Studies

KW - Heart Failure

KW - Heart Rate

KW - Humans

KW - Lipid Peroxidation

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain

KW - Oxidative Stress

KW - Stroke Volume

KW - Tetrazoles

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1016/S1388-9842(02)00002-8

DO - 10.1016/S1388-9842(02)00002-8

M3 - Article

C2 - 11959049

VL - 4

SP - 193

EP - 199

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 2

ER -